## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

- 1-45 (Canceled)
- 46. (Currently Amended) A pharmaceutical composition consisting essentially of a phosvitin or a phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof which is at least [[10%]]70% dephosphorylated and a pharmaceutically-acceptable carrier, wherein the pharmaceutical composition is not an aqueous solution or a lyophilized material.
  - 47-48 (Canceled)
- 49. (Previously presented) The composition of Claim 46 wherein the phosvitin is chicken phosvitin.
  - 50.-52. (Canceled)
- (Currently Amended) The composition of Claim 52 Claim 46 wherein the phosvitin
  or fragment thereof is at least about 90% dephosphorylated.
  - 54-80 (Canceled)
- 81. (Currently Amended) A kit for contacting a cell, a tissue or an organ that has been removed from an animal, the kit comprising:
- (a) a container holding a phosvitin or fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof-which is at least 70% dephosphorylated; and
- (b) instructions describing how to use the kit to contact a cell, tissue or organ with the phosvitin or fragment thereof in the kit.
  - 82-185 (Canceled)
- 186. (Currently Amended) A pharmaceutical composition which is formulated for topical administration to an animal and which is not an aqueous solution, the composition consisting essentially of a phosvitin or a phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof-which is at least [[10%]]70% dephosphorylated and a pharmaceutically-acceptable carrier.
  - 187-193 (Canceled)

Appl. No. 10/723,247 Amdt. dated February 3, 2011 Reply to Office Action mailed August 3, 2010

- 194. (Previously presented) The composition of Claim 186 wherein the phosvitin is chicken phosvitin.
  - 195.-198. (Canceled)
- 199. (Currently Amended) The composition of Claim 198Claim 186 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.
  - 200-216 (Canceled)
- 217. (Currently Amended) The pharmaceutical composition of any one of Claims 186, 195-199 or 288 199 or 288 which is formulated for topical administration to the skin of an animal.
- 218. (Currently Amended) The pharmaceutical composition of any one of Claims 46, 186, 195 199 or 288199 or 288 which is drops, a spray, an aerosol or an inhalant.
- 219. (Currently Amended) The pharmaceutical composition of any one of Claims 46, 186, 195 199 or 288 199 or 288 which is a powder or a foam.
- 220. (Currently Amended) The pharmaceutical composition of any one of Claims 46, 186, 495-199 or 288 199 or 288 which is a lotion, a gel, a cream, an ointment or a paste.
  - 221-245 (Canceled)
- 246. (Previously presented) The pharmaceutical composition of Claim 220 which is an ointment or a cream.
  - 247-271 (Canceled)
- 272. (Currently Amended) A pharmaceutical composition comprising a phosvitin or a phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof which is at least 10% dephosphorylated and has a targeting molecule covalently attached to it and a pharmaceutically-acceptable carrier.
- 273. (Previously presented) The composition of Claim 272 wherein the composition is formulated for topical administration to an animal.
  - 274-279 (Canceled)
  - 280. (Canceled)
- 281. (Previously presented) The composition of Claim 53 wherein the phosvitin or fragment thereof is unphosphorylated.
  - 282.-285 (Canceled)

Appl. No. 10/723,247 Amdt. dated February 3, 2011 Reply to Office Action mailed August 3, 2010

- 286. (Currently Amended) The composition of Claim 285Claim 49 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.
- 287. (Previously presented) The composition of Claim 286 wherein the phosvitin or fragment thereof is unphosphorylated.
- 288. (Previously presented) The composition of Claim 199 wherein the phosvitin or fragment thereof is unphosphorylated.
  - 289.-292 (Canceled)
- 293. (Currently Amended) The composition of Claim 292 Claim 194 wherein the phosyitin or fragment thereof is at least about 90% dephosphorylated.
- 294. (Previously Presented) The composition of Claim 293 wherein the phosvitin or fragment thereof is unphosphorylated.
- 295. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is formulated for topical administration to the skin of an animal.
- 296. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is drops, a spray, an aerosol or an inhalant.
- 297. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is a powder or a foam.
- 298. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is a lotion, a gel, a cream, an ointment or a paste.
- 299. (Previously Presented) The pharmaceutical composition of Claim 298 which is an ointment or a cream.